We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+64.75%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$415M
AUM Growth
-$87.3M
Cap. Flow
-$197M
Cap. Flow %
-47.49%
Top 10 Hldgs %
52.5%
Holding
125
New
21
Increased
12
Reduced
28
Closed
39

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$11.8M
2
PCVX icon
Vaxcyte
PCVX
+$9.81M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7M
4
RCUS icon
Arcus Biosciences
RCUS
+$3.8M
5
BTAI icon
BioXcel Therapeutics
BTAI
+$3.78M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.8M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.03M
3
GOSS icon
Gossamer Bio
GOSS
+$4.98M
4
SAGE
Sage Therapeutics
SAGE
+$3.44M
5
SCPH
scPharmaceuticals
SCPH
+$3.13M

Sector Composition

Rank Sector Weight
1 Healthcare 57.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMMB
51
Chemomab Therapeutics
CMMB
$11.4M
$1M 0.24%
78,348
+16,874
+27% +$146K
IMUX icon
52
Immunic
IMUX
$190M
$910K 0.22%
+65,000
New +$1.77M
COGT icon
53
Cogent Biosciences
COGT
$6.65B
$726K 0.18%
62,766
-100,000
-61% -$1.24M
OCUL icon
54
Ocular Therapeutix
OCUL
$1.79B
$562K 0.14%
200,000
-65,000
-25% -$215K
ELDN icon
55
Eledon Pharmaceuticals
ELDN
$261M
$515K 0.12%
221,830
– –
TARA icon
56
Protara Therapeutics
TARA
$220M
$506K 0.12%
188,664
– –
BIIB icon
57
CALL
Biogen
BIIB
$30B
$498K 0.12%
1,800
-68,700
-97% -$19.4M
DSGN icon
58
PUT
Design Therapeutics
DSGN
$761M
$498K 0.12%
48,500
– –
AUTL
59
Autolus Therapeutics
AUTL
$397M
$494K 0.12%
260,087
– –
IMVT icon
60
CALL
Immunovant
IMVT
$7.93B
$465K 0.11%
+26,200
New +$330K
IMTX icon
61
Immatics
IMTX
$1.18B
$427K 0.1%
49,031
– –
ANEB
62
DELISTED
Anebulo Pharmaceuticals
ANEB
$375K 0.09%
156,203
– –
OKUR
63
OnKure Therapeutics
OKUR
$154M
$363K 0.09%
15,582
– –
GERN icon
64
PUT
Geron
GERN
$828M
$363K 0.09%
+150,000
New +$336K
PRAX icon
65
Praxis Precision Medicines
PRAX
$8.58B
$357K 0.09%
+10,000
New +$312K
XFOR icon
66
X4 Pharmaceuticals
XFOR
$375M
$347K 0.08%
11,638
-7,316
-39% -$347K
BLCM
67
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$323K 0.08%
448,101
– –
BCLI
68
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$311K 0.08%
12,662
– –
CABA icon
69
Cabaletta Bio
CABA
$437M
$280K 0.07%
30,286
-138,337
-82% -$504K
BIIB icon
70
Biogen
BIIB
$30B
$266K 0.06%
962
-10,000
-91% -$2.82M
SYBX
71
DELISTED
Synlogic
SYBX
$233K 0.06%
20,450
– –
RLMD icon
72
Relmada Therapeutics
RLMD
$557M
$229K 0.06%
+65,491
New +$575K
CNTB
73
Connect Biopharma Holdings
CNTB
$127M
$190K 0.05%
219,501
– –
ASLN
74
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$151K 0.04%
20,511
– –
ARKK icon
75
ARK Innovation ETF
ARKK
$5.64B
$141K 0.03%
4,519
– –
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Ikarian Capital held 125 positions worth $415M, down 17% from $502M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Ikarian Capital withdrew a net $197M in Q4 2022, closing 39 positions and reducing 28 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $5.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 39% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Biohaven worth $11.6M.

  • Ikarian Capital's largest Q4 2022 buy was Biohaven: 837,500 shares worth $11.6M.
  • Ikarian Capital added most to Prometheus Biosciences, Inc. Common Stock in Q4 2022, an estimated $3.74M increase.
  • Ikarian Capital's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $12.8M.
  • Ikarian Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $5.03M.
  • Ikarian Capital's ten largest holdings make up 53% of its $415M portfolio in Q4 2022.
  • Ikarian Capital opened 21 new positions and closed 39 in Q4 2022.
  • Ikarian Capital's portfolio value fell 17% quarter-over-quarter to $415M.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.